Athena Countouriotis
President and Chief Executive Officer at Turning Point Therapeutics
Meet Athena Countouriotis
Countouriotis’ experience includes large and small molecule therapeutics in hematologic and solid tumor indications, with multiple regulatory approvals in the US and Europe. In 2018, Countouriotis joined Turning Point Therapeutics’ board of directors and also became the company’s President and Chief Executive Officer. She also serves on the board of directors of Iovance Biotherapeutics and Passage Bio. “The speedy development of COVID-19 vaccines may provide a template for some drug development projects. Though that approach won’t apply in all settings, ‘speed’ is an attribute we value and recognize at Turning Point. We see it as our duty to bring differentiated therapies to patients as rapidly as possible, which leads us to think creatively and collaboratively with regulatory agencies about important topics like trial design.”